The Study to Assess the Safety and Efficacy of OCU400 for Retinitis Pigmentosa
Status:
Not yet recruiting
Trial end date:
2023-04-01
Target enrollment:
Participant gender:
Summary
This is a multicenter, open-label, dose ranging study to assess the safety of unilateral
subretinal administration of OCU400 in subjects with NR2E3-related retinitis pigmentosa.